- Home
- EXEL vs ELAN Comparison
EXEL vs ELAN Comparison
Compare EXEL & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | ELAN |
|---|---|---|
| Founded | 1994 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 10.3B |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EXEL | ELAN |
|---|---|---|
| Price | $43.88 | $22.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 10 |
| Target Price | ★ $45.18 | $23.11 |
| AVG Volume (30 Days) | 2.6M | ★ 5.9M |
| Earning Date | 02-10-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.55 | N/A |
| EPS | ★ 2.38 | 0.07 |
| Revenue | $2,288,218,000.00 | ★ $4,591,000,000.00 |
| Revenue This Year | $9.79 | $7.25 |
| Revenue Next Year | $12.01 | $5.73 |
| P/E Ratio | ★ $18.44 | $312.33 |
| Revenue Growth | ★ 9.93 | 3.08 |
| 52 Week Low | $31.90 | $8.02 |
| 52 Week High | $49.62 | $23.70 |
Technical Indicators
Market Signals| Indicator | EXEL | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 57.06 |
| Support Level | $40.83 | $21.95 |
| Resistance Level | $47.24 | $22.57 |
| Average True Range (ATR) | 1.11 | 0.48 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 48.94 | 79.24 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.